Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Gastrointestinal Stromal Tumors | 93 | 2022 | 615 | 12.000 |
Why?
|
Sarcoma | 74 | 2024 | 1785 | 8.890 |
Why?
|
Piperazines | 73 | 2021 | 2511 | 5.660 |
Why?
|
Pyrimidines | 79 | 2021 | 3006 | 5.610 |
Why?
|
Antineoplastic Agents, Alkylating | 26 | 2021 | 617 | 5.010 |
Why?
|
Gastrointestinal Neoplasms | 46 | 2022 | 951 | 4.130 |
Why?
|
Proto-Oncogene Proteins c-kit | 60 | 2021 | 726 | 4.100 |
Why?
|
Dioxoles | 18 | 2017 | 95 | 4.050 |
Why?
|
Pyrroles | 35 | 2016 | 1130 | 4.010 |
Why?
|
Benzamides | 76 | 2022 | 1368 | 3.930 |
Why?
|
Indoles | 35 | 2016 | 1828 | 3.530 |
Why?
|
Liposarcoma | 15 | 2019 | 283 | 3.470 |
Why?
|
Leiomyosarcoma | 19 | 2022 | 424 | 3.380 |
Why?
|
Antineoplastic Agents | 114 | 2021 | 13591 | 3.290 |
Why?
|
Tetrahydroisoquinolines | 18 | 2017 | 81 | 3.280 |
Why?
|
Soft Tissue Neoplasms | 27 | 2023 | 1152 | 2.420 |
Why?
|
Protein Kinase Inhibitors | 49 | 2023 | 5629 | 2.400 |
Why?
|
Dacarbazine | 8 | 2021 | 559 | 2.290 |
Why?
|
Phenylurea Compounds | 14 | 2019 | 529 | 2.130 |
Why?
|
Drug Resistance, Neoplasm | 39 | 2021 | 5248 | 1.660 |
Why?
|
Doxorubicin | 16 | 2024 | 2209 | 1.630 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 47 | 2024 | 11709 | 1.450 |
Why?
|
Disease-Free Survival | 55 | 2018 | 6821 | 1.380 |
Why?
|
Bone Neoplasms | 13 | 2023 | 2531 | 1.350 |
Why?
|
Protein-Tyrosine Kinases | 25 | 2022 | 2416 | 1.290 |
Why?
|
Antibiotics, Antineoplastic | 7 | 2014 | 675 | 1.190 |
Why?
|
Pyridines | 17 | 2019 | 2860 | 1.170 |
Why?
|
Neoplasms | 49 | 2024 | 22030 | 1.150 |
Why?
|
Erythropoietin | 14 | 2005 | 719 | 1.130 |
Why?
|
Receptor, Platelet-Derived Growth Factor alpha | 18 | 2018 | 367 | 1.090 |
Why?
|
Isoquinolines | 8 | 2021 | 351 | 1.090 |
Why?
|
Drug Administration Schedule | 29 | 2021 | 4839 | 1.030 |
Why?
|
Angiogenesis Inhibitors | 10 | 2019 | 2047 | 0.970 |
Why?
|
Sarcoma, Synovial | 7 | 2024 | 151 | 0.950 |
Why?
|
Anemia | 13 | 2024 | 1504 | 0.850 |
Why?
|
Maximum Tolerated Dose | 10 | 2024 | 876 | 0.850 |
Why?
|
Thiazolidinediones | 8 | 2012 | 460 | 0.830 |
Why?
|
Treatment Outcome | 89 | 2024 | 64379 | 0.820 |
Why?
|
Tropomyosin | 3 | 2023 | 104 | 0.810 |
Why?
|
TOR Serine-Threonine Kinases | 11 | 2014 | 2057 | 0.800 |
Why?
|
Kaplan-Meier Estimate | 24 | 2020 | 6493 | 0.760 |
Why?
|
Indazoles | 7 | 2022 | 302 | 0.730 |
Why?
|
Ifosfamide | 8 | 2024 | 232 | 0.730 |
Why?
|
Adult | 156 | 2024 | 219916 | 0.730 |
Why?
|
Sirolimus | 7 | 2013 | 1533 | 0.720 |
Why?
|
Middle Aged | 165 | 2024 | 219560 | 0.720 |
Why?
|
Aged | 135 | 2024 | 168217 | 0.720 |
Why?
|
Humans | 337 | 2024 | 758381 | 0.720 |
Why?
|
Receptor Protein-Tyrosine Kinases | 10 | 2021 | 1613 | 0.680 |
Why?
|
Anthracyclines | 4 | 2020 | 282 | 0.670 |
Why?
|
Ketones | 2 | 2017 | 183 | 0.660 |
Why?
|
Furans | 2 | 2017 | 199 | 0.650 |
Why?
|
Thrombocytopenia | 8 | 2024 | 1172 | 0.640 |
Why?
|
Uterine Neoplasms | 6 | 2017 | 1439 | 0.640 |
Why?
|
Medical Oncology | 10 | 2021 | 2312 | 0.630 |
Why?
|
Pyrazoles | 6 | 2023 | 1990 | 0.610 |
Why?
|
Neutropenia | 13 | 2019 | 884 | 0.610 |
Why?
|
Neoplasm Recurrence, Local | 18 | 2021 | 9273 | 0.600 |
Why?
|
Hematopoietic Cell Growth Factors | 7 | 1995 | 98 | 0.590 |
Why?
|
Clinical Trials, Phase II as Topic | 10 | 2021 | 627 | 0.590 |
Why?
|
Granulocyte Colony-Stimulating Factor | 14 | 2014 | 629 | 0.590 |
Why?
|
Aged, 80 and over | 58 | 2021 | 58681 | 0.580 |
Why?
|
Benzothiazoles | 1 | 2018 | 246 | 0.580 |
Why?
|
Female | 187 | 2024 | 390316 | 0.580 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 16 | 2015 | 886 | 0.550 |
Why?
|
Chromans | 6 | 2004 | 117 | 0.550 |
Why?
|
Immunoconjugates | 2 | 2021 | 949 | 0.540 |
Why?
|
Male | 160 | 2024 | 358742 | 0.540 |
Why?
|
Colony-Stimulating Factors | 13 | 2007 | 218 | 0.540 |
Why?
|
Stromal Cells | 12 | 2004 | 1326 | 0.520 |
Why?
|
Treatment Failure | 10 | 2017 | 2640 | 0.510 |
Why?
|
Survival Analysis | 27 | 2024 | 10112 | 0.500 |
Why?
|
Thiazoles | 6 | 2009 | 1511 | 0.490 |
Why?
|
Survival Rate | 26 | 2021 | 12721 | 0.490 |
Why?
|
Molecular Targeted Therapy | 8 | 2021 | 2796 | 0.480 |
Why?
|
fms-Like Tyrosine Kinase 3 | 1 | 2018 | 495 | 0.480 |
Why?
|
Receptor, trkA | 5 | 2023 | 159 | 0.470 |
Why?
|
Enzyme Inhibitors | 5 | 2002 | 3709 | 0.470 |
Why?
|
Benzofurans | 1 | 2014 | 140 | 0.460 |
Why?
|
Oncogene Proteins, Fusion | 10 | 2023 | 1594 | 0.450 |
Why?
|
Clinical Trials as Topic | 16 | 2024 | 7985 | 0.450 |
Why?
|
Benzoquinones | 2 | 2013 | 198 | 0.440 |
Why?
|
Young Adult | 44 | 2022 | 58808 | 0.430 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 3 | 2022 | 5246 | 0.430 |
Why?
|
Compassionate Use Trials | 1 | 2013 | 50 | 0.430 |
Why?
|
Mutation | 41 | 2020 | 29915 | 0.420 |
Why?
|
Quinolines | 3 | 2013 | 759 | 0.420 |
Why?
|
Lung Neoplasms | 14 | 2022 | 13245 | 0.420 |
Why?
|
Decision Making | 4 | 2021 | 3915 | 0.420 |
Why?
|
Salvage Therapy | 6 | 2019 | 1268 | 0.410 |
Why?
|
Biological Products | 1 | 2021 | 906 | 0.410 |
Why?
|
Lactams, Macrocyclic | 2 | 2013 | 315 | 0.410 |
Why?
|
Retroperitoneal Neoplasms | 5 | 2004 | 329 | 0.400 |
Why?
|
Phthalazines | 1 | 2014 | 382 | 0.400 |
Why?
|
Hydroxamic Acids | 1 | 2014 | 481 | 0.390 |
Why?
|
Pyrrolidinones | 1 | 2012 | 116 | 0.390 |
Why?
|
Liposarcoma, Myxoid | 3 | 2024 | 60 | 0.390 |
Why?
|
Outpatients | 1 | 2019 | 1591 | 0.380 |
Why?
|
Sulfonamides | 5 | 2021 | 1973 | 0.380 |
Why?
|
Serine | 1 | 2015 | 828 | 0.370 |
Why?
|
Gene Fusion | 4 | 2023 | 354 | 0.370 |
Why?
|
Deoxycytidine | 4 | 2020 | 870 | 0.370 |
Why?
|
Translocation, Genetic | 5 | 2012 | 1387 | 0.370 |
Why?
|
Disease Progression | 22 | 2018 | 13468 | 0.360 |
Why?
|
Carbolines | 2 | 2024 | 286 | 0.350 |
Why?
|
Microphthalmia-Associated Transcription Factor | 1 | 2012 | 259 | 0.350 |
Why?
|
Infusions, Intravenous | 12 | 2011 | 2210 | 0.350 |
Why?
|
Neoplasm Metastasis | 12 | 2024 | 4901 | 0.340 |
Why?
|
PPAR gamma | 2 | 2012 | 482 | 0.340 |
Why?
|
HSP90 Heat-Shock Proteins | 4 | 2016 | 423 | 0.340 |
Why?
|
Hematinics | 3 | 2005 | 280 | 0.340 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2014 | 772 | 0.340 |
Why?
|
Administration, Oral | 10 | 2021 | 3993 | 0.340 |
Why?
|
Adolescent | 40 | 2023 | 87888 | 0.340 |
Why?
|
Evidence-Based Medicine | 2 | 2021 | 3671 | 0.330 |
Why?
|
Cisplatin | 2 | 2015 | 1645 | 0.320 |
Why?
|
Retreatment | 3 | 2017 | 596 | 0.320 |
Why?
|
Proto-Oncogene Proteins c-met | 2 | 2012 | 567 | 0.320 |
Why?
|
Succinate Dehydrogenase | 4 | 2019 | 145 | 0.310 |
Why?
|
Clinical Trials, Phase III as Topic | 6 | 2021 | 851 | 0.310 |
Why?
|
Carcinoma, Small Cell | 3 | 1996 | 416 | 0.310 |
Why?
|
Oncogenes | 6 | 2020 | 1221 | 0.310 |
Why?
|
Oncogene Proteins | 5 | 2004 | 719 | 0.310 |
Why?
|
Recombinant Proteins | 26 | 2009 | 6520 | 0.310 |
Why?
|
Chemotherapy, Adjuvant | 16 | 2017 | 3527 | 0.310 |
Why?
|
Dose-Response Relationship, Drug | 19 | 2016 | 10747 | 0.310 |
Why?
|
Heart | 1 | 2021 | 4382 | 0.300 |
Why?
|
Inpatients | 1 | 2019 | 2551 | 0.300 |
Why?
|
Mesoderm | 3 | 2002 | 672 | 0.290 |
Why?
|
Combined Modality Therapy | 16 | 2017 | 8530 | 0.290 |
Why?
|
MAP Kinase Kinase 4 | 1 | 2007 | 149 | 0.290 |
Why?
|
Growth Substances | 7 | 2002 | 768 | 0.280 |
Why?
|
Thrombospondin 1 | 1 | 2008 | 257 | 0.280 |
Why?
|
Research Subjects | 2 | 2007 | 249 | 0.280 |
Why?
|
Hemangiosarcoma | 2 | 2020 | 216 | 0.270 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 5 | 2020 | 544 | 0.260 |
Why?
|
Benzenesulfonates | 3 | 2012 | 165 | 0.260 |
Why?
|
Vascular Endothelial Growth Factor A | 6 | 2011 | 3480 | 0.250 |
Why?
|
Neovascularization, Pathologic | 4 | 2012 | 2638 | 0.250 |
Why?
|
Immunohistochemistry | 17 | 2019 | 11070 | 0.250 |
Why?
|
Gene Expression Regulation, Neoplastic | 12 | 2021 | 8506 | 0.250 |
Why?
|
Rare Diseases | 2 | 2021 | 619 | 0.250 |
Why?
|
DNA Mutational Analysis | 12 | 2020 | 4106 | 0.250 |
Why?
|
Antigens, Neoplasm | 4 | 2022 | 1997 | 0.250 |
Why?
|
Drug Monitoring | 2 | 2009 | 960 | 0.250 |
Why?
|
Molecular Biology | 2 | 2011 | 580 | 0.240 |
Why?
|
Double-Blind Method | 11 | 2015 | 12262 | 0.240 |
Why?
|
Proportional Hazards Models | 11 | 2017 | 12440 | 0.240 |
Why?
|
Receptor, IGF Type 1 | 3 | 2012 | 380 | 0.240 |
Why?
|
Ovarian Neoplasms | 3 | 2021 | 4876 | 0.240 |
Why?
|
Proto-Oncogene Proteins | 6 | 2022 | 4485 | 0.240 |
Why?
|
Sarcoma, Alveolar Soft Part | 2 | 2015 | 43 | 0.220 |
Why?
|
Safety | 5 | 2016 | 1147 | 0.220 |
Why?
|
Fusion Proteins, bcr-abl | 2 | 2007 | 431 | 0.220 |
Why?
|
Neoplasm Staging | 15 | 2019 | 11152 | 0.220 |
Why?
|
Biopsy, Needle | 3 | 2012 | 1630 | 0.220 |
Why?
|
Cell Proliferation | 13 | 2021 | 10417 | 0.220 |
Why?
|
Receptor, trkC | 2 | 2020 | 63 | 0.220 |
Why?
|
Fatigue | 5 | 2017 | 1542 | 0.220 |
Why?
|
Sarcoma, Clear Cell | 2 | 2015 | 72 | 0.220 |
Why?
|
Bone Marrow Diseases | 3 | 1994 | 232 | 0.210 |
Why?
|
Oligopeptides | 1 | 2008 | 1185 | 0.210 |
Why?
|
Tetrahydronaphthalenes | 1 | 2003 | 86 | 0.210 |
Why?
|
United States Food and Drug Administration | 2 | 2021 | 1660 | 0.210 |
Why?
|
Prognosis | 24 | 2022 | 29558 | 0.210 |
Why?
|
Neoplasms, Connective Tissue | 1 | 2002 | 36 | 0.210 |
Why?
|
Gene Expression Profiling | 7 | 2020 | 9405 | 0.210 |
Why?
|
Breast Neoplasms | 15 | 2020 | 21017 | 0.210 |
Why?
|
Alanine Transaminase | 3 | 2017 | 604 | 0.210 |
Why?
|
Informed Consent | 2 | 2007 | 1003 | 0.200 |
Why?
|
Retrospective Studies | 29 | 2022 | 80170 | 0.200 |
Why?
|
Receptor, trkB | 2 | 2020 | 125 | 0.200 |
Why?
|
Child | 17 | 2023 | 79813 | 0.200 |
Why?
|
Quality of Life | 11 | 2021 | 13286 | 0.200 |
Why?
|
Phosphorylation | 15 | 2014 | 8297 | 0.190 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 4 | 2016 | 855 | 0.190 |
Why?
|
Membrane Proteins | 6 | 2022 | 7843 | 0.190 |
Why?
|
Triazoles | 3 | 2019 | 902 | 0.190 |
Why?
|
Placebos | 3 | 2012 | 1661 | 0.190 |
Why?
|
Clinical Trials, Phase I as Topic | 4 | 2019 | 326 | 0.190 |
Why?
|
Receptors, CCR | 1 | 2021 | 37 | 0.190 |
Why?
|
Xenograft Model Antitumor Assays | 6 | 2021 | 3574 | 0.190 |
Why?
|
International Cooperation | 3 | 2018 | 1430 | 0.190 |
Why?
|
Positron-Emission Tomography | 8 | 2013 | 6457 | 0.190 |
Why?
|
Drug Resistance, Multiple | 1 | 2002 | 253 | 0.180 |
Why?
|
Carcinoma, Renal Cell | 3 | 2012 | 3217 | 0.180 |
Why?
|
Transcription Factors | 8 | 2021 | 12096 | 0.180 |
Why?
|
Sulfides | 1 | 2021 | 170 | 0.180 |
Why?
|
SKP Cullin F-Box Protein Ligases | 1 | 2021 | 175 | 0.180 |
Why?
|
Antibodies, Monoclonal | 4 | 2012 | 9160 | 0.180 |
Why?
|
Leukopenia | 2 | 2019 | 211 | 0.180 |
Why?
|
Platinum | 1 | 2002 | 218 | 0.180 |
Why?
|
Fibromatosis, Aggressive | 3 | 2008 | 125 | 0.180 |
Why?
|
Disease Management | 4 | 2019 | 2500 | 0.180 |
Why?
|
Neoplasms, Muscle Tissue | 2 | 2010 | 67 | 0.170 |
Why?
|
Time Factors | 19 | 2019 | 39873 | 0.170 |
Why?
|
Growth Differentiation Factor 15 | 1 | 2021 | 195 | 0.170 |
Why?
|
Thigh | 2 | 1999 | 240 | 0.170 |
Why?
|
Health Records, Personal | 1 | 2020 | 127 | 0.170 |
Why?
|
Neoplasm Proteins | 4 | 2002 | 3609 | 0.170 |
Why?
|
Patient Participation | 3 | 2020 | 1436 | 0.160 |
Why?
|
Practice Guidelines as Topic | 3 | 2007 | 7377 | 0.160 |
Why?
|
Receptors, Nerve Growth Factor | 1 | 2019 | 198 | 0.160 |
Why?
|
Hemoglobin A | 1 | 1998 | 84 | 0.160 |
Why?
|
Drug Dosage Calculations | 2 | 2021 | 117 | 0.160 |
Why?
|
Polyethylene Glycols | 4 | 2021 | 1188 | 0.160 |
Why?
|
Signal Transduction | 16 | 2018 | 23341 | 0.150 |
Why?
|
Sarcoma, Small Cell | 1 | 1998 | 17 | 0.150 |
Why?
|
Drug Labeling | 1 | 2020 | 248 | 0.150 |
Why?
|
Epoetin Alfa | 4 | 2002 | 78 | 0.150 |
Why?
|
Guillain-Barre Syndrome | 1 | 2019 | 126 | 0.150 |
Why?
|
Hypertension | 4 | 2014 | 8503 | 0.150 |
Why?
|
United States | 17 | 2021 | 72140 | 0.150 |
Why?
|
Vascular Neoplasms | 2 | 2011 | 167 | 0.150 |
Why?
|
Stomach Neoplasms | 2 | 2014 | 1422 | 0.150 |
Why?
|
Somatostatin | 1 | 1999 | 447 | 0.150 |
Why?
|
Drug Approval | 2 | 2021 | 809 | 0.140 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 2 | 2021 | 1136 | 0.140 |
Why?
|
Tomography, X-Ray Computed | 16 | 2018 | 20500 | 0.140 |
Why?
|
Cyclin D1 | 1 | 2019 | 451 | 0.140 |
Why?
|
Adoptive Transfer | 1 | 2019 | 819 | 0.140 |
Why?
|
Chromosome Aberrations | 5 | 2019 | 1764 | 0.140 |
Why?
|
Aspartate Aminotransferases | 2 | 2017 | 415 | 0.140 |
Why?
|
Receptors, Antigen, T-Cell | 3 | 2022 | 2532 | 0.140 |
Why?
|
Gastrectomy | 2 | 2019 | 670 | 0.140 |
Why?
|
Cyclin-Dependent Kinase 6 | 2 | 2022 | 345 | 0.140 |
Why?
|
Proto-Oncogene Proteins c-akt | 4 | 2014 | 2443 | 0.140 |
Why?
|
Product Surveillance, Postmarketing | 1 | 2021 | 452 | 0.140 |
Why?
|
Piperidines | 2 | 2002 | 1639 | 0.140 |
Why?
|
Isoindoles | 1 | 2016 | 35 | 0.130 |
Why?
|
Leukemia, Myeloid | 2 | 2009 | 695 | 0.130 |
Why?
|
Hematopoietic Stem Cells | 8 | 1996 | 3384 | 0.130 |
Why?
|
Cytokines | 5 | 2019 | 7338 | 0.130 |
Why?
|
Uterus | 1 | 2020 | 651 | 0.130 |
Why?
|
Tumor Microenvironment | 4 | 2022 | 3840 | 0.130 |
Why?
|
Fluorodeoxyglucose F18 | 5 | 2012 | 2004 | 0.130 |
Why?
|
Hemoglobins | 6 | 2005 | 1519 | 0.130 |
Why?
|
Muscle Proteins | 1 | 2021 | 1150 | 0.130 |
Why?
|
Congresses as Topic | 1 | 2021 | 799 | 0.130 |
Why?
|
Randomized Controlled Trials as Topic | 10 | 2019 | 10146 | 0.130 |
Why?
|
Cyclin-Dependent Kinase 4 | 2 | 2022 | 555 | 0.130 |
Why?
|
Drug Design | 3 | 2007 | 1049 | 0.130 |
Why?
|
Data Collection | 2 | 2024 | 3322 | 0.130 |
Why?
|
Cell Line, Tumor | 13 | 2021 | 16886 | 0.130 |
Why?
|
Tumor Cells, Cultured | 8 | 2021 | 6127 | 0.130 |
Why?
|
Prospective Studies | 15 | 2022 | 54136 | 0.130 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2017 | 698 | 0.130 |
Why?
|
Karyopherins | 1 | 2016 | 130 | 0.130 |
Why?
|
Hematologic Neoplasms | 3 | 2008 | 1890 | 0.130 |
Why?
|
Chondrosarcoma | 2 | 2013 | 296 | 0.130 |
Why?
|
Rhabdoid Tumor | 1 | 2017 | 210 | 0.130 |
Why?
|
Republic of Korea | 2 | 2015 | 565 | 0.120 |
Why?
|
Mesothelioma | 2 | 1993 | 807 | 0.120 |
Why?
|
Pyridones | 1 | 2020 | 785 | 0.120 |
Why?
|
T-Lymphocytes | 3 | 2019 | 10171 | 0.120 |
Why?
|
Area Under Curve | 4 | 2009 | 1632 | 0.120 |
Why?
|
Animals | 34 | 2022 | 167777 | 0.120 |
Why?
|
Health Care Sector | 1 | 2016 | 193 | 0.120 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 3 | 2008 | 666 | 0.120 |
Why?
|
Abdominal Neoplasms | 2 | 2010 | 286 | 0.120 |
Why?
|
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2017 | 316 | 0.120 |
Why?
|
Cancer Vaccines | 2 | 2015 | 1046 | 0.120 |
Why?
|
Receptors, Progesterone | 2 | 2013 | 1130 | 0.120 |
Why?
|
Interleukin-3 | 3 | 1994 | 425 | 0.120 |
Why?
|
Mice, Nude | 6 | 2019 | 3602 | 0.120 |
Why?
|
Neoplasms, Second Primary | 1 | 2022 | 1056 | 0.120 |
Why?
|
Hydrazines | 1 | 2016 | 224 | 0.120 |
Why?
|
Nausea | 1 | 2017 | 677 | 0.120 |
Why?
|
Multicenter Studies as Topic | 4 | 2007 | 1705 | 0.120 |
Why?
|
Thrombopoietin | 3 | 2001 | 226 | 0.120 |
Why?
|
Neoadjuvant Therapy | 3 | 2012 | 2821 | 0.110 |
Why?
|
Exons | 6 | 2014 | 2387 | 0.110 |
Why?
|
Vascular Endothelial Growth Factors | 2 | 2012 | 747 | 0.110 |
Why?
|
Paclitaxel | 4 | 2008 | 1728 | 0.110 |
Why?
|
Proto-Oncogene Proteins c-jun | 1 | 2014 | 285 | 0.110 |
Why?
|
Genes, Wilms Tumor | 1 | 1993 | 92 | 0.110 |
Why?
|
Membrane Glycoproteins | 3 | 2020 | 3705 | 0.110 |
Why?
|
Phosphoric Diester Hydrolases | 1 | 2014 | 198 | 0.110 |
Why?
|
Phosphatidylinositol 3-Kinase | 1 | 2014 | 126 | 0.110 |
Why?
|
Chaperonins | 1 | 2013 | 58 | 0.110 |
Why?
|
Patient Satisfaction | 1 | 2005 | 3446 | 0.110 |
Why?
|
Drug Substitution | 1 | 2015 | 288 | 0.110 |
Why?
|
Alopecia | 1 | 2017 | 414 | 0.110 |
Why?
|
Dystrophin | 1 | 2014 | 284 | 0.110 |
Why?
|
Mesna | 3 | 2004 | 62 | 0.110 |
Why?
|
Point Mutation | 2 | 2000 | 1593 | 0.110 |
Why?
|
Receptors, Granulocyte Colony-Stimulating Factor | 1 | 1991 | 21 | 0.100 |
Why?
|
Sequence Deletion | 3 | 2007 | 1492 | 0.100 |
Why?
|
Mucous Membrane | 2 | 2013 | 656 | 0.100 |
Why?
|
Chromosomal Proteins, Non-Histone | 1 | 2017 | 727 | 0.100 |
Why?
|
Research Support as Topic | 1 | 2016 | 697 | 0.100 |
Why?
|
Desmoplastic Small Round Cell Tumor | 1 | 2012 | 33 | 0.100 |
Why?
|
Patient Selection | 5 | 2014 | 4244 | 0.100 |
Why?
|
Apoptosis | 9 | 2021 | 9468 | 0.100 |
Why?
|
Follow-Up Studies | 14 | 2021 | 39060 | 0.100 |
Why?
|
Cell Survival | 5 | 2021 | 5781 | 0.100 |
Why?
|
Isoenzymes | 2 | 2008 | 1686 | 0.100 |
Why?
|
Muscular Dystrophies | 1 | 2014 | 389 | 0.100 |
Why?
|
Stomatitis | 2 | 2011 | 271 | 0.100 |
Why?
|
Protein Kinase C | 2 | 2008 | 1199 | 0.100 |
Why?
|
Genes | 3 | 1991 | 1845 | 0.100 |
Why?
|
HLA-A Antigens | 2 | 2024 | 225 | 0.100 |
Why?
|
ras Proteins | 2 | 2014 | 1049 | 0.100 |
Why?
|
Sunlight | 1 | 2013 | 337 | 0.100 |
Why?
|
Homeodomain Proteins | 1 | 2021 | 2413 | 0.100 |
Why?
|
Gene Amplification | 2 | 2013 | 1085 | 0.090 |
Why?
|
Fever | 3 | 2009 | 1617 | 0.090 |
Why?
|
Stem Cell Factor | 3 | 2004 | 195 | 0.090 |
Why?
|
Hematopoietic Stem Cell Transplantation | 7 | 2001 | 5649 | 0.090 |
Why?
|
PTEN Phosphohydrolase | 1 | 2017 | 1113 | 0.090 |
Why?
|
Receptors, Estrogen | 2 | 2013 | 2211 | 0.090 |
Why?
|
Gynecologic Surgical Procedures | 1 | 2014 | 304 | 0.090 |
Why?
|
Cross-Over Studies | 3 | 2012 | 2048 | 0.090 |
Why?
|
Multivariate Analysis | 3 | 2021 | 12096 | 0.090 |
Why?
|
Endothelin-1 | 1 | 2012 | 302 | 0.090 |
Why?
|
Comprehension | 2 | 2007 | 619 | 0.090 |
Why?
|
Tomography, Emission-Computed | 3 | 2003 | 1121 | 0.090 |
Why?
|
Genes, ras | 2 | 2008 | 654 | 0.090 |
Why?
|
Extracellular Fluid | 1 | 2012 | 165 | 0.090 |
Why?
|
Diagnostic Imaging | 3 | 2012 | 3526 | 0.090 |
Why?
|
Drug Screening Assays, Antitumor | 2 | 2016 | 714 | 0.090 |
Why?
|
Radiotherapy, Adjuvant | 5 | 2002 | 1791 | 0.090 |
Why?
|
Cell Respiration | 1 | 2010 | 202 | 0.090 |
Why?
|
Age Factors | 5 | 2021 | 18357 | 0.090 |
Why?
|
Half-Life | 2 | 2009 | 652 | 0.090 |
Why?
|
Drug Industry | 1 | 2016 | 787 | 0.090 |
Why?
|
Leukemia, Myelomonocytic, Acute | 1 | 1989 | 38 | 0.090 |
Why?
|
Extremities | 4 | 2004 | 865 | 0.090 |
Why?
|
Serous Membrane | 1 | 1989 | 24 | 0.090 |
Why?
|
Drug Delivery Systems | 2 | 2015 | 2211 | 0.090 |
Why?
|
Interferon-alpha | 1 | 2014 | 918 | 0.090 |
Why?
|
Cyclophosphamide | 5 | 2008 | 2218 | 0.090 |
Why?
|
Granuloma, Plasma Cell | 1 | 2010 | 80 | 0.090 |
Why?
|
Cell Division | 8 | 2004 | 4459 | 0.090 |
Why?
|
Rhabdomyolysis | 1 | 2011 | 153 | 0.090 |
Why?
|
Irritants | 1 | 2009 | 43 | 0.090 |
Why?
|
Immunotherapy, Adoptive | 1 | 2019 | 1454 | 0.080 |
Why?
|
Aromatase Inhibitors | 1 | 2013 | 511 | 0.080 |
Why?
|
Connective Tissue | 2 | 2022 | 416 | 0.080 |
Why?
|
Kidney Neoplasms | 4 | 2012 | 4312 | 0.080 |
Why?
|
Intracellular Signaling Peptides and Proteins | 2 | 2010 | 2872 | 0.080 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2019 | 2825 | 0.080 |
Why?
|
Phosphatidylinositol 3-Kinases | 5 | 2013 | 2858 | 0.080 |
Why?
|
Perivascular Epithelioid Cell Neoplasms | 1 | 2010 | 77 | 0.080 |
Why?
|
Cell Cycle | 6 | 2017 | 2930 | 0.080 |
Why?
|
Receptor, Platelet-Derived Growth Factor beta | 5 | 2008 | 184 | 0.080 |
Why?
|
Mucositis | 1 | 2010 | 108 | 0.080 |
Why?
|
Mice | 18 | 2022 | 81107 | 0.080 |
Why?
|
Vascular Endothelial Growth Factor Receptor-3 | 1 | 2009 | 119 | 0.080 |
Why?
|
Stroke Volume | 2 | 2021 | 5460 | 0.080 |
Why?
|
Taxoids | 1 | 2012 | 668 | 0.080 |
Why?
|
Nitriles | 1 | 2013 | 957 | 0.080 |
Why?
|
Thiophenes | 1 | 2013 | 569 | 0.080 |
Why?
|
Liver | 4 | 2017 | 7502 | 0.080 |
Why?
|
Biological Factors | 1 | 1989 | 157 | 0.080 |
Why?
|
Karyotyping | 3 | 2005 | 1171 | 0.080 |
Why?
|
Skin Ulcer | 1 | 2009 | 129 | 0.080 |
Why?
|
Ventricular Function, Left | 1 | 2021 | 3858 | 0.080 |
Why?
|
Vaccines, Subunit | 1 | 2008 | 161 | 0.080 |
Why?
|
Carboplatin | 3 | 2008 | 788 | 0.080 |
Why?
|
Cardiotoxins | 1 | 2007 | 36 | 0.080 |
Why?
|
Diarrhea | 1 | 2015 | 1317 | 0.070 |
Why?
|
Pharmacogenetics | 1 | 2012 | 675 | 0.070 |
Why?
|
Soft Tissue Injuries | 1 | 2009 | 172 | 0.070 |
Why?
|
Thromboplastin | 1 | 1989 | 286 | 0.070 |
Why?
|
Drug Discovery | 1 | 2015 | 1044 | 0.070 |
Why?
|
Drug Tolerance | 1 | 2009 | 367 | 0.070 |
Why?
|
Mesentery | 1 | 2008 | 202 | 0.070 |
Why?
|
Solubility | 1 | 2009 | 1087 | 0.070 |
Why?
|
Hematopoiesis | 6 | 1994 | 2047 | 0.070 |
Why?
|
Transcription, Genetic | 6 | 2005 | 7590 | 0.070 |
Why?
|
Patients | 1 | 2014 | 904 | 0.070 |
Why?
|
Melanoma | 3 | 2013 | 5691 | 0.070 |
Why?
|
Cardiovascular Diseases | 3 | 2021 | 15396 | 0.070 |
Why?
|
Blood Transfusion | 4 | 2005 | 1321 | 0.070 |
Why?
|
Enzyme Activation | 6 | 2013 | 3593 | 0.070 |
Why?
|
Blood Coagulation Factors | 1 | 1989 | 365 | 0.070 |
Why?
|
Cell Movement | 3 | 2014 | 5201 | 0.070 |
Why?
|
In Situ Hybridization, Fluorescence | 5 | 2014 | 2504 | 0.070 |
Why?
|
Imidazoles | 1 | 2013 | 1179 | 0.070 |
Why?
|
Patient Education as Topic | 3 | 2007 | 2307 | 0.070 |
Why?
|
Protein Kinase C-delta | 1 | 2007 | 114 | 0.070 |
Why?
|
Blotting, Western | 5 | 2016 | 5031 | 0.070 |
Why?
|
Cell Differentiation | 6 | 2014 | 11471 | 0.070 |
Why?
|
Benzimidazoles | 1 | 2012 | 855 | 0.070 |
Why?
|
Fatal Outcome | 3 | 2000 | 1829 | 0.070 |
Why?
|
Genomics | 2 | 2020 | 5789 | 0.070 |
Why?
|
Spectrometry, Fluorescence | 1 | 2009 | 681 | 0.070 |
Why?
|
Research Design | 3 | 2024 | 6154 | 0.070 |
Why?
|
Oligodeoxyribonucleotides | 1 | 2008 | 778 | 0.070 |
Why?
|
Academic Medical Centers | 1 | 2016 | 2751 | 0.070 |
Why?
|
Genotype | 5 | 2016 | 12945 | 0.070 |
Why?
|
Diagnosis, Differential | 4 | 2004 | 12951 | 0.070 |
Why?
|
K562 Cells | 1 | 2007 | 639 | 0.070 |
Why?
|
Platelet-Derived Growth Factor | 3 | 2006 | 617 | 0.060 |
Why?
|
Australia | 1 | 2009 | 1235 | 0.060 |
Why?
|
Kidney Diseases | 1 | 2016 | 2083 | 0.060 |
Why?
|
North America | 1 | 2009 | 1276 | 0.060 |
Why?
|
Remission Induction | 3 | 2002 | 2388 | 0.060 |
Why?
|
Proteins | 2 | 2019 | 6026 | 0.060 |
Why?
|
Consensus | 3 | 2022 | 3099 | 0.060 |
Why?
|
Filgrastim | 4 | 2009 | 132 | 0.060 |
Why?
|
Teaching Materials | 1 | 2005 | 84 | 0.060 |
Why?
|
Genetic Predisposition to Disease | 3 | 2019 | 17768 | 0.060 |
Why?
|
Rhabdomyosarcoma | 2 | 2014 | 358 | 0.060 |
Why?
|
Polymerase Chain Reaction | 3 | 2009 | 6068 | 0.060 |
Why?
|
Proteinuria | 1 | 2008 | 594 | 0.060 |
Why?
|
Europe | 2 | 2009 | 3420 | 0.060 |
Why?
|
Forecasting | 3 | 2005 | 2920 | 0.060 |
Why?
|
Platelet Count | 2 | 2002 | 775 | 0.060 |
Why?
|
Bone Cysts, Aneurysmal | 1 | 2005 | 70 | 0.060 |
Why?
|
Dermatofibrosarcoma | 1 | 2005 | 48 | 0.060 |
Why?
|
Colorectal Neoplasms | 2 | 2021 | 6852 | 0.060 |
Why?
|
Vena Cava, Inferior | 1 | 2007 | 458 | 0.060 |
Why?
|
Gene Expression | 4 | 2022 | 7583 | 0.060 |
Why?
|
Interferon-gamma | 2 | 1989 | 3156 | 0.060 |
Why?
|
Niacinamide | 3 | 2012 | 414 | 0.060 |
Why?
|
History, 18th Century | 1 | 2004 | 207 | 0.060 |
Why?
|
Oligonucleotide Array Sequence Analysis | 3 | 2014 | 3774 | 0.060 |
Why?
|
Clone Cells | 1 | 2007 | 1660 | 0.060 |
Why?
|
Chromosomes, Human, Pair 17 | 1 | 2005 | 419 | 0.060 |
Why?
|
Biopsy | 4 | 2019 | 6768 | 0.060 |
Why?
|
CHO Cells | 3 | 2019 | 1389 | 0.060 |
Why?
|
Nurse's Role | 1 | 2005 | 188 | 0.060 |
Why?
|
Injections, Subcutaneous | 2 | 2002 | 677 | 0.060 |
Why?
|
Patient-Centered Care | 1 | 2013 | 1415 | 0.050 |
Why?
|
Nitric Oxide | 1 | 2012 | 2131 | 0.050 |
Why?
|
Telomerase | 1 | 2008 | 745 | 0.050 |
Why?
|
Toremifene | 1 | 2003 | 24 | 0.050 |
Why?
|
Syndrome | 2 | 2010 | 3262 | 0.050 |
Why?
|
Estrogen Receptor Modulators | 1 | 2003 | 58 | 0.050 |
Why?
|
Gene Rearrangement | 2 | 2005 | 1122 | 0.050 |
Why?
|
DNA-Binding Proteins | 4 | 2005 | 9575 | 0.050 |
Why?
|
Advisory Committees | 1 | 2007 | 785 | 0.050 |
Why?
|
Analysis of Variance | 2 | 2015 | 6233 | 0.050 |
Why?
|
Tumor Burden | 3 | 2014 | 1893 | 0.050 |
Why?
|
Leukocyte Count | 4 | 2009 | 1593 | 0.050 |
Why?
|
Protective Agents | 1 | 2003 | 150 | 0.050 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 4 | 2016 | 4567 | 0.050 |
Why?
|
Models, Economic | 1 | 2007 | 715 | 0.050 |
Why?
|
Sex Factors | 2 | 2011 | 10505 | 0.050 |
Why?
|
Neoplasms, Experimental | 1 | 2007 | 1228 | 0.050 |
Why?
|
Bone Marrow Transplantation | 3 | 1996 | 2693 | 0.050 |
Why?
|
Antigens, CD34 | 1 | 2004 | 653 | 0.050 |
Why?
|
Infrared Rays | 1 | 2003 | 245 | 0.050 |
Why?
|
Drug Evaluation, Preclinical | 2 | 2012 | 1335 | 0.050 |
Why?
|
Cyclin-Dependent Kinase 2 | 1 | 2022 | 184 | 0.050 |
Why?
|
Peritoneal Neoplasms | 1 | 2008 | 707 | 0.050 |
Why?
|
Antigens, Surface | 2 | 2001 | 1607 | 0.050 |
Why?
|
Enhancer Elements, Genetic | 2 | 2019 | 1356 | 0.050 |
Why?
|
RNA, Small Interfering | 4 | 2014 | 3433 | 0.050 |
Why?
|
Multidrug Resistance-Associated Proteins | 1 | 2002 | 105 | 0.050 |
Why?
|
Hypothyroidism | 1 | 2006 | 665 | 0.050 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2024 | 278 | 0.050 |
Why?
|
Cell Cycle Proteins | 1 | 2013 | 3443 | 0.050 |
Why?
|
Blood Pressure | 3 | 2012 | 8453 | 0.050 |
Why?
|
Skin Neoplasms | 3 | 2013 | 5797 | 0.050 |
Why?
|
Germ-Line Mutation | 2 | 2010 | 1840 | 0.050 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 1989 | 4342 | 0.050 |
Why?
|
Feasibility Studies | 4 | 2009 | 5199 | 0.050 |
Why?
|
Interleukin-11 | 1 | 2001 | 58 | 0.050 |
Why?
|
Cohort Studies | 9 | 2014 | 41252 | 0.050 |
Why?
|
Protein Processing, Post-Translational | 2 | 2013 | 1972 | 0.040 |
Why?
|
Rats | 3 | 2021 | 23681 | 0.040 |
Why?
|
Inflammation | 1 | 2020 | 10719 | 0.040 |
Why?
|
Drug Interactions | 1 | 2005 | 1414 | 0.040 |
Why?
|
Haplorhini | 1 | 2021 | 529 | 0.040 |
Why?
|
Thyroid Hormones | 1 | 2003 | 403 | 0.040 |
Why?
|
Fibroblast Growth Factor 4 | 1 | 2019 | 28 | 0.040 |
Why?
|
Sequence Analysis, RNA | 2 | 2022 | 2001 | 0.040 |
Why?
|
Indium Radioisotopes | 1 | 1999 | 113 | 0.040 |
Why?
|
GTP Phosphohydrolases | 2 | 2013 | 517 | 0.040 |
Why?
|
Neuroectodermal Tumors | 1 | 1999 | 22 | 0.040 |
Why?
|
T-Cell Antigen Receptor Specificity | 1 | 2019 | 85 | 0.040 |
Why?
|
Leukemia, Myeloid, Acute | 4 | 2006 | 3599 | 0.040 |
Why?
|
Erythrocyte Transfusion | 2 | 2001 | 563 | 0.040 |
Why?
|
Mitotic Index | 2 | 2014 | 161 | 0.040 |
Why?
|
Genes, p53 | 2 | 2012 | 712 | 0.040 |
Why?
|
Angiomyolipoma | 1 | 2001 | 184 | 0.040 |
Why?
|
Case Management | 1 | 2001 | 272 | 0.040 |
Why?
|
Rectal Neoplasms | 1 | 2008 | 1152 | 0.040 |
Why?
|
HEK293 Cells | 2 | 2019 | 4258 | 0.040 |
Why?
|
Guidelines as Topic | 1 | 2005 | 1386 | 0.040 |
Why?
|
Gene Expression Regulation | 4 | 1990 | 11894 | 0.040 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2003 | 623 | 0.040 |
Why?
|
Base Sequence | 6 | 2008 | 12436 | 0.040 |
Why?
|
Receptors, Fibroblast Growth Factor | 1 | 2019 | 192 | 0.040 |
Why?
|
Risk Factors | 11 | 2022 | 73806 | 0.040 |
Why?
|
Vinblastine | 3 | 2008 | 487 | 0.040 |
Why?
|
Physical Examination | 1 | 2005 | 1244 | 0.040 |
Why?
|
Evolution, Molecular | 1 | 2007 | 1885 | 0.040 |
Why?
|
Octreotide | 1 | 1999 | 153 | 0.040 |
Why?
|
Radiation Tolerance | 1 | 2001 | 480 | 0.040 |
Why?
|
Odds Ratio | 2 | 2008 | 9650 | 0.040 |
Why?
|
Disease Models, Animal | 2 | 2022 | 18125 | 0.040 |
Why?
|
Back | 1 | 1998 | 64 | 0.040 |
Why?
|
Tamoxifen | 1 | 2003 | 963 | 0.040 |
Why?
|
Incidence | 4 | 2021 | 21273 | 0.040 |
Why?
|
Gene Dosage | 2 | 2014 | 1218 | 0.040 |
Why?
|
Neoplasm Invasiveness | 3 | 2014 | 3617 | 0.040 |
Why?
|
Liver Neoplasms | 4 | 2002 | 4313 | 0.040 |
Why?
|
DNA, Neoplasm | 5 | 2003 | 1745 | 0.040 |
Why?
|
Radiotherapy | 1 | 2005 | 1504 | 0.040 |
Why?
|
Risk Assessment | 5 | 2012 | 23883 | 0.040 |
Why?
|
Tissue Distribution | 1 | 2002 | 2263 | 0.040 |
Why?
|
Mutation, Missense | 2 | 2013 | 2564 | 0.040 |
Why?
|
Health Services Needs and Demand | 1 | 2005 | 1401 | 0.040 |
Why?
|
Osteosarcoma | 1 | 2003 | 897 | 0.040 |
Why?
|
Zinc Fingers | 2 | 2004 | 568 | 0.040 |
Why?
|
Phosphatidylcholines | 1 | 1999 | 405 | 0.040 |
Why?
|
Morpholines | 1 | 2020 | 580 | 0.040 |
Why?
|
Dendritic Cells | 1 | 2008 | 2723 | 0.040 |
Why?
|
Pedigree | 1 | 2005 | 4578 | 0.040 |
Why?
|
Radiography, Interventional | 1 | 2004 | 1112 | 0.040 |
Why?
|
RNA, Messenger | 6 | 1993 | 12760 | 0.040 |
Why?
|
Cricetulus | 1 | 2019 | 815 | 0.040 |
Why?
|
SEER Program | 1 | 2022 | 1530 | 0.030 |
Why?
|
Genetic Complementation Test | 1 | 2017 | 555 | 0.030 |
Why?
|
Azepines | 1 | 2019 | 329 | 0.030 |
Why?
|
Macrophage Colony-Stimulating Factor | 3 | 1992 | 186 | 0.030 |
Why?
|
Japan | 1 | 2021 | 1366 | 0.030 |
Why?
|
Rats, Sprague-Dawley | 1 | 2007 | 8144 | 0.030 |
Why?
|
Blotting, Northern | 3 | 1993 | 1543 | 0.030 |
Why?
|
Protein Kinases | 2 | 2018 | 1610 | 0.030 |
Why?
|
Chromosomes, Human, Pair 14 | 1 | 2017 | 286 | 0.030 |
Why?
|
Radiography | 1 | 2007 | 6955 | 0.030 |
Why?
|
Enterocolitis, Pseudomembranous | 1 | 1998 | 264 | 0.030 |
Why?
|
Drug Therapy, Combination | 2 | 2021 | 6293 | 0.030 |
Why?
|
Ultrasonography, Interventional | 1 | 2004 | 1489 | 0.030 |
Why?
|
Interleukin-1 | 2 | 1990 | 1249 | 0.030 |
Why?
|
Leukocytes, Mononuclear | 2 | 1996 | 1826 | 0.030 |
Why?
|
Interleukins | 2 | 1992 | 783 | 0.030 |
Why?
|
Urogenital Neoplasms | 2 | 2008 | 135 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 7 | 2008 | 36285 | 0.030 |
Why?
|
Chromosomes, Human, Pair 22 | 1 | 1997 | 346 | 0.030 |
Why?
|
Neuroectodermal Tumors, Primitive | 1 | 1997 | 136 | 0.030 |
Why?
|
Hypoglycemic Agents | 1 | 2008 | 3069 | 0.030 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2019 | 1351 | 0.030 |
Why?
|
Chromosomes, Human, Pair 11 | 1 | 1997 | 410 | 0.030 |
Why?
|
Biphenyl Compounds | 1 | 2020 | 988 | 0.030 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2020 | 895 | 0.030 |
Why?
|
Ligands | 2 | 2000 | 3258 | 0.030 |
Why?
|
Immunoenzyme Techniques | 3 | 2004 | 1705 | 0.030 |
Why?
|
Neurofibromin 1 | 1 | 2017 | 190 | 0.030 |
Why?
|
MAP Kinase Signaling System | 2 | 2013 | 1477 | 0.030 |
Why?
|
Ambulatory Care | 2 | 2005 | 2768 | 0.030 |
Why?
|
Receptors, Colony-Stimulating Factor | 2 | 1992 | 50 | 0.030 |
Why?
|
Polymorphism, Single Nucleotide | 5 | 2014 | 15773 | 0.030 |
Why?
|
Health Services Accessibility | 1 | 2013 | 5403 | 0.030 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 2 | 2014 | 1725 | 0.030 |
Why?
|
Molecular Sequence Data | 5 | 2008 | 17617 | 0.030 |
Why?
|
RNA, Neoplasm | 3 | 2000 | 749 | 0.030 |
Why?
|
Algorithms | 2 | 2013 | 13959 | 0.030 |
Why?
|
Neutrophils | 3 | 2009 | 3765 | 0.030 |
Why?
|
Heart Diseases | 1 | 2007 | 2782 | 0.030 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 1999 | 1066 | 0.030 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2003 | 1530 | 0.030 |
Why?
|
Reactive Oxygen Species | 1 | 2022 | 2129 | 0.030 |
Why?
|
Lymphoma | 1 | 2003 | 1896 | 0.030 |
Why?
|
Interstitial Cells of Cajal | 1 | 2014 | 23 | 0.030 |
Why?
|
Canada | 1 | 2020 | 2111 | 0.030 |
Why?
|
Isoleucine | 1 | 2014 | 110 | 0.030 |
Why?
|
Bone Marrow | 3 | 1996 | 2909 | 0.030 |
Why?
|
Germinoma | 1 | 1995 | 132 | 0.030 |
Why?
|
Pilot Projects | 5 | 2008 | 8554 | 0.030 |
Why?
|
DNA, Complementary | 3 | 2002 | 1991 | 0.030 |
Why?
|
Injections, Intravenous | 1 | 2016 | 1378 | 0.030 |
Why?
|
STAT1 Transcription Factor | 2 | 2007 | 333 | 0.030 |
Why?
|
Genetic Engineering | 1 | 2019 | 933 | 0.030 |
Why?
|
Cost-Benefit Analysis | 1 | 2007 | 5484 | 0.030 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 1086 | 0.030 |
Why?
|
Cell Dedifferentiation | 1 | 2014 | 122 | 0.030 |
Why?
|
Program Development | 1 | 2020 | 1297 | 0.030 |
Why?
|
Pentacyclic Triterpenes | 1 | 2013 | 35 | 0.030 |
Why?
|
Threonine | 1 | 2014 | 270 | 0.030 |
Why?
|
Oligonucleotide Probes | 1 | 1993 | 416 | 0.030 |
Why?
|
Chromatin Assembly and Disassembly | 1 | 2017 | 633 | 0.030 |
Why?
|
Leukapheresis | 3 | 2001 | 134 | 0.030 |
Why?
|
Nephrology | 1 | 2016 | 263 | 0.030 |
Why?
|
Vincristine | 1 | 1995 | 1038 | 0.030 |
Why?
|
Triterpenes | 1 | 2013 | 74 | 0.030 |
Why?
|
Sensitivity and Specificity | 3 | 2007 | 14641 | 0.030 |
Why?
|
Melanocytes | 1 | 1996 | 509 | 0.030 |
Why?
|
WT1 Proteins | 1 | 1993 | 184 | 0.030 |
Why?
|
Endothelium, Vascular | 1 | 2005 | 4429 | 0.030 |
Why?
|
Drug Resistance | 1 | 1998 | 1593 | 0.030 |
Why?
|
Cells, Cultured | 4 | 2014 | 18942 | 0.030 |
Why?
|
Kinetics | 3 | 2007 | 6371 | 0.030 |
Why?
|
Inhibitory Concentration 50 | 1 | 2013 | 462 | 0.030 |
Why?
|
Muscle Development | 1 | 2014 | 259 | 0.030 |
Why?
|
Chromosome Deletion | 1 | 2017 | 1387 | 0.030 |
Why?
|
Genital Neoplasms, Female | 2 | 2008 | 533 | 0.020 |
Why?
|
Blood Platelets | 1 | 2002 | 2475 | 0.020 |
Why?
|
Predictive Value of Tests | 3 | 2009 | 15225 | 0.020 |
Why?
|
Amino Acid Sequence | 4 | 2001 | 13447 | 0.020 |
Why?
|
Proto-Oncogene Protein c-fli-1 | 1 | 2012 | 104 | 0.020 |
Why?
|
Genome, Human | 2 | 2020 | 4415 | 0.020 |
Why?
|
Angiogenic Proteins | 1 | 2012 | 101 | 0.020 |
Why?
|
Tissue Array Analysis | 1 | 2013 | 551 | 0.020 |
Why?
|
Recurrence | 2 | 2001 | 8426 | 0.020 |
Why?
|
Promoter Regions, Genetic | 2 | 2017 | 5779 | 0.020 |
Why?
|
Triglycerides | 1 | 1999 | 2450 | 0.020 |
Why?
|
Expert Testimony | 1 | 2013 | 361 | 0.020 |
Why?
|
Electron Transport Complex II | 1 | 2010 | 53 | 0.020 |
Why?
|
STAT3 Transcription Factor | 2 | 2007 | 869 | 0.020 |
Why?
|
Reference Values | 2 | 1996 | 4919 | 0.020 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2005 | 3990 | 0.020 |
Why?
|
Mitosis | 1 | 1996 | 1191 | 0.020 |
Why?
|
Feedback, Physiological | 1 | 2013 | 475 | 0.020 |
Why?
|
Glycine | 1 | 2014 | 662 | 0.020 |
Why?
|
Retinoblastoma Protein | 1 | 2014 | 670 | 0.020 |
Why?
|
RNA-Binding Protein EWS | 1 | 2012 | 210 | 0.020 |
Why?
|
Gene Silencing | 1 | 2017 | 1507 | 0.020 |
Why?
|
Neoplasm Transplantation | 1 | 2014 | 2013 | 0.020 |
Why?
|
Arginine | 1 | 2014 | 933 | 0.020 |
Why?
|
Gene Library | 1 | 2013 | 1059 | 0.020 |
Why?
|
Cell Separation | 1 | 1996 | 1720 | 0.020 |
Why?
|
Receptors, Cell Surface | 2 | 1990 | 2825 | 0.020 |
Why?
|
Lentivirus | 1 | 2013 | 503 | 0.020 |
Why?
|
Receptors, Growth Factor | 1 | 2010 | 326 | 0.020 |
Why?
|
Genes, Tumor Suppressor | 1 | 2014 | 1055 | 0.020 |
Why?
|
Drug Therapy | 1 | 2013 | 503 | 0.020 |
Why?
|
Tyrosine | 2 | 2007 | 1432 | 0.020 |
Why?
|
Cricetinae | 2 | 2003 | 2426 | 0.020 |
Why?
|
Population | 1 | 2009 | 140 | 0.020 |
Why?
|
Receptor, Macrophage Colony-Stimulating Factor | 1 | 1989 | 94 | 0.020 |
Why?
|
In Situ Hybridization | 1 | 1993 | 1900 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2020 | 2912 | 0.020 |
Why?
|
Peritoneal Cavity | 1 | 1989 | 138 | 0.020 |
Why?
|
Body Weight | 2 | 2014 | 4603 | 0.020 |
Why?
|
Leukemia, Experimental | 1 | 1989 | 225 | 0.020 |
Why?
|
Paraganglioma | 1 | 2010 | 142 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2012 | 640 | 0.020 |
Why?
|
Extravasation of Diagnostic and Therapeutic Materials | 1 | 2009 | 101 | 0.020 |
Why?
|
Mast Cells | 1 | 1996 | 1390 | 0.020 |
Why?
|
Depression | 1 | 2008 | 8057 | 0.020 |
Why?
|
Cloning, Molecular | 2 | 1991 | 4169 | 0.020 |
Why?
|
Fibromatosis, Abdominal | 1 | 2008 | 21 | 0.020 |
Why?
|
Central Nervous System Neoplasms | 2 | 2008 | 916 | 0.020 |
Why?
|
Severity of Illness Index | 2 | 2009 | 15785 | 0.020 |
Why?
|
Acute Disease | 2 | 2009 | 7225 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2022 | 4549 | 0.020 |
Why?
|
Research | 2 | 2008 | 1976 | 0.020 |
Why?
|
Proto-Oncogenes | 1 | 1989 | 320 | 0.020 |
Why?
|
Uteroglobin | 1 | 2008 | 56 | 0.020 |
Why?
|
Pressure | 1 | 2012 | 1155 | 0.020 |
Why?
|
Kidney Failure, Chronic | 1 | 2001 | 2457 | 0.020 |
Why?
|
AMP-Activated Protein Kinases | 1 | 2012 | 597 | 0.020 |
Why?
|
Transplantation, Autologous | 3 | 2000 | 2114 | 0.020 |
Why?
|
Repetitive Sequences, Nucleic Acid | 1 | 1990 | 783 | 0.020 |
Why?
|
Capillary Permeability | 1 | 2012 | 769 | 0.020 |
Why?
|
Drug Evaluation | 1 | 1989 | 638 | 0.020 |
Why?
|
Neoplasm Seeding | 1 | 2008 | 84 | 0.020 |
Why?
|
Lactones | 1 | 1990 | 317 | 0.020 |
Why?
|
Blood Cells | 1 | 1990 | 305 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 3801 | 0.020 |
Why?
|
Health Care Costs | 1 | 2001 | 3245 | 0.020 |
Why?
|
World Health Organization | 1 | 2014 | 1312 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2014 | 3425 | 0.020 |
Why?
|
Lymphatic Metastasis | 2 | 2008 | 2943 | 0.020 |
Why?
|
History, 16th Century | 1 | 2007 | 70 | 0.020 |
Why?
|
Protein Subunits | 1 | 2010 | 942 | 0.020 |
Why?
|
History, 17th Century | 1 | 2007 | 107 | 0.020 |
Why?
|
Nonlinear Dynamics | 1 | 2009 | 493 | 0.020 |
Why?
|
Toll-Like Receptor 9 | 1 | 2008 | 234 | 0.020 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 1994 | 1096 | 0.020 |
Why?
|
Chromosomes, Human, Pair 1 | 1 | 1989 | 635 | 0.020 |
Why?
|
Pancreatic Neoplasms | 1 | 2005 | 5349 | 0.020 |
Why?
|
Costs and Cost Analysis | 1 | 1993 | 1673 | 0.020 |
Why?
|
Decision Trees | 1 | 2009 | 504 | 0.020 |
Why?
|
Consent Forms | 1 | 2007 | 55 | 0.020 |
Why?
|
Endpoint Determination | 1 | 2009 | 590 | 0.020 |
Why?
|
Antigen-Presenting Cells | 1 | 1990 | 964 | 0.020 |
Why?
|
Gene Deletion | 1 | 2014 | 2666 | 0.020 |
Why?
|
Thyroiditis | 1 | 2006 | 86 | 0.020 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2010 | 664 | 0.020 |
Why?
|
Epigenesis, Genetic | 1 | 2019 | 3754 | 0.020 |
Why?
|
Structure-Activity Relationship | 1 | 1991 | 3069 | 0.020 |
Why?
|
Chromosome Mapping | 2 | 1991 | 4624 | 0.020 |
Why?
|
Chromatin | 1 | 2017 | 2938 | 0.020 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 1993 | 1373 | 0.020 |
Why?
|
Genes, sis | 1 | 2005 | 3 | 0.020 |
Why?
|
Drug Synergism | 1 | 1989 | 1745 | 0.020 |
Why?
|
Models, Biological | 2 | 2013 | 9461 | 0.020 |
Why?
|
DNA Methylation | 1 | 2019 | 4373 | 0.020 |
Why?
|
Hodgkin Disease | 1 | 1993 | 1377 | 0.020 |
Why?
|
Iron | 2 | 1994 | 1786 | 0.020 |
Why?
|
Necrosis | 1 | 2009 | 1604 | 0.020 |
Why?
|
Mice, Transgenic | 2 | 2008 | 9518 | 0.020 |
Why?
|
Financing, Government | 1 | 2008 | 472 | 0.020 |
Why?
|
Albumins | 1 | 2008 | 575 | 0.020 |
Why?
|
Mice, Inbred BALB C | 1 | 2014 | 6209 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-sis | 1 | 2006 | 255 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2017 | 3615 | 0.020 |
Why?
|
Epithelium | 1 | 1989 | 1605 | 0.010 |
Why?
|
Immunoprecipitation | 1 | 2007 | 877 | 0.010 |
Why?
|
Catheterization, Central Venous | 1 | 2009 | 526 | 0.010 |
Why?
|
Anastomosis, Surgical | 1 | 2008 | 983 | 0.010 |
Why?
|
Device Removal | 1 | 2009 | 633 | 0.010 |
Why?
|
Myelodysplastic Syndromes | 1 | 1994 | 1392 | 0.010 |
Why?
|
Hemoglobinometry | 1 | 2004 | 35 | 0.010 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2012 | 1927 | 0.010 |
Why?
|
Propionates | 1 | 2005 | 182 | 0.010 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2007 | 412 | 0.010 |
Why?
|
Leukemia | 1 | 1992 | 1519 | 0.010 |
Why?
|
Bone and Bones | 1 | 1994 | 2560 | 0.010 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1993 | 1547 | 0.010 |
Why?
|
Drainage | 1 | 2009 | 1161 | 0.010 |
Why?
|
Genetic Association Studies | 1 | 2013 | 2717 | 0.010 |
Why?
|
Topotecan | 1 | 2004 | 132 | 0.010 |
Why?
|
Mice, Mutant Strains | 1 | 2007 | 1751 | 0.010 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 1992 | 2197 | 0.010 |
Why?
|
Interleukin-6 | 2 | 1990 | 3208 | 0.010 |
Why?
|
Heart Failure | 1 | 2007 | 11594 | 0.010 |
Why?
|
Multiprotein Complexes | 1 | 2010 | 1120 | 0.010 |
Why?
|
Thyrotropin | 1 | 2006 | 832 | 0.010 |
Why?
|
Gallium Radioisotopes | 1 | 2003 | 195 | 0.010 |
Why?
|
Receptors, Immunologic | 1 | 1989 | 1411 | 0.010 |
Why?
|
Sequence Analysis, DNA | 1 | 2014 | 4711 | 0.010 |
Why?
|
Adjuvants, Immunologic | 1 | 2008 | 1038 | 0.010 |
Why?
|
Immunoblotting | 1 | 2006 | 1647 | 0.010 |
Why?
|
Cell Communication | 1 | 1990 | 1651 | 0.010 |
Why?
|
Carcinoma | 1 | 2014 | 2330 | 0.010 |
Why?
|
Adrenal Cortex Hormones | 1 | 2011 | 1870 | 0.010 |
Why?
|
Head and Neck Neoplasms | 2 | 2007 | 2882 | 0.010 |
Why?
|
Neuroblastoma | 1 | 2010 | 1251 | 0.010 |
Why?
|
Hormone Replacement Therapy | 1 | 2007 | 754 | 0.010 |
Why?
|
Proteoglycans | 1 | 2005 | 801 | 0.010 |
Why?
|
Reproducibility of Results | 2 | 2012 | 20052 | 0.010 |
Why?
|
Collagen Type I | 1 | 2005 | 616 | 0.010 |
Why?
|
Transaminases | 1 | 2002 | 196 | 0.010 |
Why?
|
Lipopolysaccharides | 1 | 1989 | 2204 | 0.010 |
Why?
|
Biomedical Research | 2 | 2007 | 3417 | 0.010 |
Why?
|
Neoplastic Stem Cells | 1 | 1989 | 1346 | 0.010 |
Why?
|
Lymphocytes | 1 | 1989 | 2610 | 0.010 |
Why?
|
Risk | 1 | 2013 | 9599 | 0.010 |
Why?
|
Ecdysone | 1 | 1980 | 19 | 0.010 |
Why?
|
Melanoma-Specific Antigens | 1 | 2001 | 74 | 0.010 |
Why?
|
Fluorine Radioisotopes | 1 | 2003 | 413 | 0.010 |
Why?
|
Cell Line | 3 | 2010 | 15594 | 0.010 |
Why?
|
Lung | 1 | 1999 | 9985 | 0.010 |
Why?
|
Liver Function Tests | 1 | 2002 | 523 | 0.010 |
Why?
|
beta Catenin | 1 | 2006 | 1043 | 0.010 |
Why?
|
Toxicity Tests | 1 | 2001 | 112 | 0.010 |
Why?
|
N-Acetylneuraminic Acid | 1 | 2001 | 173 | 0.010 |
Why?
|
Cross-Cultural Comparison | 1 | 2004 | 635 | 0.010 |
Why?
|
Mutagenesis, Site-Directed | 1 | 2003 | 1693 | 0.010 |
Why?
|
Zebrafish | 1 | 2011 | 2993 | 0.010 |
Why?
|
Monocytes | 1 | 1989 | 2570 | 0.010 |
Why?
|
Linear Models | 1 | 2009 | 5861 | 0.010 |
Why?
|
Tumor Suppressor Proteins | 1 | 2010 | 2800 | 0.010 |
Why?
|
Lung Diseases | 1 | 1989 | 1910 | 0.010 |
Why?
|
Melphalan | 1 | 2001 | 420 | 0.010 |
Why?
|
Muscle, Skeletal | 1 | 2014 | 4902 | 0.010 |
Why?
|
Models, Chemical | 1 | 2001 | 610 | 0.010 |
Why?
|
Fee-for-Service Plans | 1 | 2004 | 701 | 0.010 |
Why?
|
Cost Savings | 1 | 2004 | 918 | 0.010 |
Why?
|
Managed Care Programs | 1 | 2004 | 939 | 0.010 |
Why?
|
Chronic Disease | 1 | 2013 | 9266 | 0.010 |
Why?
|
Confidence Intervals | 1 | 2004 | 2925 | 0.010 |
Why?
|
Radiopharmaceuticals | 1 | 2007 | 2634 | 0.010 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2003 | 1245 | 0.010 |
Why?
|
RNA Interference | 1 | 2006 | 2836 | 0.010 |
Why?
|
C-Reactive Protein | 1 | 1989 | 3812 | 0.010 |
Why?
|
Drug Utilization | 1 | 2004 | 1187 | 0.010 |
Why?
|
Stem Cell Transplantation | 1 | 2006 | 1599 | 0.010 |
Why?
|
Prostatic Neoplasms | 1 | 2000 | 11336 | 0.010 |
Why?
|
Child, Preschool | 2 | 2018 | 42058 | 0.010 |
Why?
|
Thiotepa | 1 | 1997 | 66 | 0.010 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2001 | 2753 | 0.010 |
Why?
|
Nucleic Acid Hybridization | 2 | 1989 | 1304 | 0.010 |
Why?
|
Erythropoiesis | 1 | 2001 | 682 | 0.010 |
Why?
|
Temperature | 1 | 2003 | 2219 | 0.010 |
Why?
|
Palliative Care | 1 | 2012 | 3570 | 0.010 |
Why?
|
Transplantation, Heterologous | 1 | 2005 | 2378 | 0.010 |
Why?
|
RNA-Directed DNA Polymerase | 1 | 1997 | 224 | 0.010 |
Why?
|
RNA-Binding Proteins | 1 | 2005 | 1895 | 0.010 |
Why?
|
Phenotype | 1 | 2014 | 16534 | 0.010 |
Why?
|
Up-Regulation | 1 | 2005 | 4114 | 0.010 |
Why?
|
DNA Probes | 1 | 1997 | 543 | 0.010 |
Why?
|
Infant | 1 | 2018 | 36054 | 0.010 |
Why?
|
Transfection | 1 | 2003 | 5779 | 0.010 |
Why?
|
Societies, Medical | 1 | 2007 | 3891 | 0.010 |
Why?
|
DNA Primers | 1 | 2000 | 2816 | 0.010 |
Why?
|
DNA | 1 | 1989 | 7199 | 0.010 |
Why?
|
Dexamethasone | 1 | 2002 | 1927 | 0.010 |
Why?
|
Reticulocyte Count | 1 | 1994 | 36 | 0.010 |
Why?
|
Technetium | 1 | 1994 | 321 | 0.010 |
Why?
|
Regression Analysis | 1 | 2004 | 6353 | 0.010 |
Why?
|
Blood Component Transfusion | 1 | 1994 | 141 | 0.010 |
Why?
|
Etoposide | 1 | 1995 | 630 | 0.010 |
Why?
|
Trans-Activators | 1 | 2003 | 2860 | 0.010 |
Why?
|
Hyperplasia | 1 | 1996 | 1154 | 0.010 |
Why?
|
Genome | 1 | 2000 | 1739 | 0.010 |
Why?
|
Multiple Myeloma | 1 | 1989 | 5129 | 0.010 |
Why?
|
Drosophila melanogaster | 1 | 1980 | 1709 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2007 | 14354 | 0.010 |
Why?
|
Health Expenditures | 1 | 2004 | 2348 | 0.010 |
Why?
|
Bryostatins | 1 | 1990 | 24 | 0.010 |
Why?
|
Radionuclide Imaging | 1 | 1994 | 1975 | 0.010 |
Why?
|
Mental Disorders | 1 | 1989 | 6803 | 0.010 |
Why?
|
Fluorouracil | 1 | 1994 | 1631 | 0.010 |
Why?
|
Macrolides | 1 | 1990 | 205 | 0.010 |
Why?
|
Receptors, Lymphocyte Homing | 1 | 1989 | 141 | 0.010 |
Why?
|
L-Selectin | 1 | 1989 | 209 | 0.010 |
Why?
|
Anaphylaxis | 1 | 1996 | 755 | 0.000 |
Why?
|
Restriction Mapping | 1 | 1989 | 852 | 0.000 |
Why?
|
Cryopreservation | 1 | 1993 | 717 | 0.000 |
Why?
|
Sequence Homology, Nucleic Acid | 1 | 1989 | 1055 | 0.000 |
Why?
|
Methotrexate | 1 | 1994 | 1719 | 0.000 |
Why?
|
Granulocytes | 1 | 1989 | 550 | 0.000 |
Why?
|
Plasmids | 1 | 1989 | 2275 | 0.000 |
Why?
|
Cell Adhesion Molecules | 1 | 1989 | 1600 | 0.000 |
Why?
|
Cell Adhesion | 1 | 1989 | 3090 | 0.000 |
Why?
|
Skin | 1 | 1996 | 4464 | 0.000 |
Why?
|
Antibodies | 1 | 1990 | 2420 | 0.000 |
Why?
|
Enzyme Induction | 1 | 1980 | 451 | 0.000 |
Why?
|
Molecular Weight | 1 | 1980 | 2185 | 0.000 |
Why?
|
B-Lymphocytes | 1 | 1989 | 4738 | 0.000 |
Why?
|
Protein Biosynthesis | 1 | 1980 | 2105 | 0.000 |
Why?
|